ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Correlation Between Cytokines and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus

This study is currently recruiting participants.
Verified by UPECLIN HC FM Botucatu Unesp, September 2008

Sponsored by: UPECLIN HC FM Botucatu Unesp
Information provided by: UPECLIN HC FM Botucatu Unesp
ClinicalTrials.gov Identifier: NCT00499434
  Purpose

This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with histopathological hepatic biopsy findings in individuals with HIV/HCV coinfection. This population will be divided into three groups (G1: with no HAART; G2: with detected HIV viral load (HIV VL); G3: with undetected HIV VL), which will be then compared to two control groups with monoinfection by HIV or by HCV, in addition to a third control group comprising normal blood donors.


Condition
Acquired Immune Deficiency Syndrome
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
HIV Infections

MedlinePlus related topics:   AIDS    Hepatitis    Hepatitis C   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Cohort, Prospective
Official Title:   Correlation Between Values of Serum Cytokines and of Those Dosed by mRNA Expression Through the Use of Real-Time PCR and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus

Further study details as provided by UPECLIN HC FM Botucatu Unesp:

Primary Outcome Measures:
  • This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with histopathological hepatic biopsy findings in individuals with HIV/HCV coinfection [ Time Frame: Two years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with CD4 and HIV viremia values in individuals with HIV/HCV coinfection [ Time Frame: Two years ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment:   110
Study Start Date:   August 2007
Estimated Study Completion Date:   April 2009
Estimated Primary Completion Date:   August 2008 (Final data collection date for primary outcome measure)

Detailed Description:

Infection by the hepatitis-C virus (HCV) in people living with HIV/AIDS (PLHA) has progressively gained distinction since the survival increase generated by the use of highly active antiretroviral therapy (HAART) has enabled the presentation of complications from HCV chronic infection. There are approximately 10 million coinfected individuals, that is, 25% of the total PLHA as both viruses share transmission routes.

HCV infection can be regarded as an opportunistic disease in this population once there is the acceleration of its natural history represented by the HCV high viral load, early hepatic fibrosis and greater occurrence of steatosis, cirrhosis and hepatocellular carcinoma, leading to greater morbid-mortality by terminal hepatic disease. The scenario is not also favorable as regards HCV treatment, since the response rate in coinfected individuals is significantly lower than in mono-infected HCV patients.

The complex relationship between immune response and HCV determines the velocity and the distinct outcomes found. The major determinant for the development of cirrhosis and hepatic insufficiency is the accumulation of fibrosis and inflammatory activity closely related to collagen synthesis by fibroblasts and hepatocyte-apoptosis induction related to TGF-β production. In individuals with more severe hepatic lesion, there is the prevalence of expression of the Th-2 profile in the peripheral blood, which is characterized by high levels of IL-4 and IL-10, whereas, in the hepatic tissue, a larger expression of cytokines of the Th-1 profile, such as IL-2 and INF-γ, is observed. This phenomenon is known as "compartmentalization" of the immune response.

If the immunopathogenic dynamics is already complex in HCV mono-infected individuals, in the HIV/HCV coinfection condition, few studies specifically approach the topic, without, however, evaluating the correlation between specific T-cell response and hepatic-lesion staging. In HIV mono-infected patients without antiretroviral treatment and with disease progression, the prevalence of the Th-0/Th-2 profile is observed, which is particularly influenced by IL-10 increase. Even in individuals treated by HAART, there is no recovery of the capacity to express the Th-1 profile, and most of such patients show the mature Th-0 profile and low IL-2 levels.

HCV viral load in PLHA is higher in both the plasma and the hepatic tissue, and the replication of HCV in macrophages, CD4 and CD8 T lymphocytes as well as in lymphnodes is also observed in such condition. TGF-β is particularly high in this coinfection, thus justifying the onset of faster fibrosis. The reduction of CD8 T lymphocyte response to IFN-γ also occurs, which favors the persistence of infection and prevents specific T-cell response. As regards HIV treatment, there is evidence that coinfected patients non-treated by HAART tend to present a Th-2 profile more often than treated individuals, without, however, significant differences in TGF-β levels.

Due to the lack of studies correlating the production tendencies of both pro-inflammatory and fibrogenesis-inducing cytokines with histopathological findings from hepatic biopsy in coinfected individuals, investigations are necessary in order establish parameters that will allow the prediction of a better or worse prognosis and also more accurately indicate the performance of hepatic biopsy.

This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with histopathological hepatic biopsy findings in individuals with HIV/HCV coinfection. This population will be divided into three groups (G1: with no HAART; G2: with detected HIV viral load (HIV VL); G3: with undetected HIV VL), which will be then compared to two control groups with monoinfection by HIV or by HCV, in addition to a third control group comprising normal blood donors.

  Eligibility
Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample

Study Population

SAE e Hospital Dia de Aids patients


Criteria

Inclusion Criteria:

  • Diagnosis of HIV infection or aids
  • Diagnosis of chronic hepatitis C

Exclusion Criteria:

  • Other hepatic diseases
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00499434

Contacts
Contact: Alexandre N Barbosa, MD, MSc     + 55 014 3811-6537     alexnaime@fmb.unesp.br    

Locations
Brazil, Sao Paulo
SAE e Hospital Dia de Aids     Recruiting
      Botucatu, Sao Paulo, Brazil, 18618970
      Contact: Alexandre N Barbosa, MD, MSc     +55 014 3811-6537     alexnaime@fmb.unesp.br    
      Principal Investigator: Alexandre N Barbosa, MD, MSc            

Sponsors and Collaborators
UPECLIN HC FM Botucatu Unesp

Investigators
Principal Investigator:     Alexandre N Barbosa, MD, MSc     UPECLIN HC FM Botucatu Unesp    
  More Information


Responsible Party:   SAE e Hospital Dia de Aids - Faculdade de Medicina de Botucatu - Unesp ( Alexandre Naime Barbosa )
Study ID Numbers:   upeclin/HC/FMB-Unesp-14
First Received:   July 10, 2007
Last Updated:   September 4, 2008
ClinicalTrials.gov Identifier:   NCT00499434
Health Authority:   Brazil: National Committee of Ethics in Research

Keywords provided by UPECLIN HC FM Botucatu Unesp:
aids  

Study placed in the following topic categories:
Virus Diseases
Hepatitis
Liver Diseases
Sexually Transmitted Diseases, Viral
Digestive System Diseases
HIV Infections
Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Hepatitis, Viral, Human
Hepatitis C
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:
RNA Virus Infections
Pathologic Processes
Disease
Slow Virus Diseases
Flaviviridae Infections
Immune System Diseases
Syndrome
Lentivirus Infections
Infection

ClinicalTrials.gov processed this record on October 06, 2008




Links to all studies - primarily for crawlers